How it works
What is NASH/NAFLD?
Am I diagnosed with NASH/NALFD?
Why use LIVERFASt™ as the first-line diagnostic test?
How does LIVERFASt™ stratify NAFLD/NASH patients?
How LIVERFASt™ helps in COVID-19 ?
Why liver health is important for diabetes ?
How LIVERFASt™ helps in diabetes ?
How does LIVERFASt™ monitor the prognosis of Chronic Hepatitis B and C patients ?
Simulating clinical confidence intervals
Comparative assessment liver lesions
Predictive value of non-invasive methods
Patient Use Cases
Is an innovative screening, diagnosis and monitoring tool for a
COMPLETE LIVER EVALUATION
and primary liver cancer prevention
Fibronostics Secures Financing,
announces new CEO
for NAFLD, NASH,
HCV, HBV, Cirrhosis.
Help quantify and monitor liver damage in subjects with metabolic risk and fatty liver as well with viral hepatitis.
Fibronostics listed in the
promising AI-driven companies
in life science
A Healthcare Technology Company
Shaping the future of noninvasive diagnosis with artificial intelligence.
Uniquely Positioned among Noninvasive technologies
A combination of broadly available biomarkers and neural network-based AI provides a diagnostics accuracy equivalent to biopsy.
CPT Code: 0166U
Complete Liver Diagnosis
LIVERFASt™ – from Early Stage to Late Stage
for NAFLD, NASH Cirrhosis that provides prognosis for liver-related hard outcomes including HCC
Risk stratification among large patient populations allows for better management leading to cost reductions.
Noninvasive disease detection means earlier diagnosis and earlier intervention for better patient outcomes.
Regular surveillance with easily repeatable noninvasive diagnostics enables optimized disease management.
Noninvasive solutions for diagnosis, screening and monitoring.
Learn more about our science
Forgot password ?
Forgot password ?